Literature DB >> 23386694

Predictive biomarkers to anti-VEGF therapy: progress toward an elusive goal.

Rekha Gyanchandani1, Seungwon Kim.   

Abstract

The search for reliable biomarkers predictive of response to anti-VEGF therapy has been elusive. VEGF-A, the therapeutic target of bevacizumab, is an intuitive candidate as a predictive biomarker to bevacizumab-based anticancer therapy. However, there remains much controversy in the use of VEGF-A as a predictor of response to bevacizumab. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23386694      PMCID： PMC3580199          DOI： 10.1158/1078-0432.CCR-12-3585

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

Review 1.  Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis.

Authors:  Apostolos Christopoulos; Sun M Ahn; Jonah D Klein; Seungwon Kim
Journal:  Head Neck       Date:  2010-12-16       Impact factor: 3.147

2.  Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

Authors:  Adrian M Jubb; Herbert I Hurwitz; Wei Bai; Eric B Holmgren; Patti Tobin; A Steven Guerrero; Fairooz Kabbinavar; Scott N Holden; William F Novotny; Gretchen D Frantz; Kenneth J Hillan; Hartmut Koeppen
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

3.  Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.

Authors:  Priti S Hegde; Adrian M Jubb; Dafeng Chen; Nicole F Li; Y Gloria Meng; Coen Bernaards; Rebecca Elliott; Stefan J Scherer; Daniel S Chen
Journal:  Clin Cancer Res       Date:  2012-11-20       Impact factor: 12.531

4.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

Authors:  Nicholas J Robert; Véronique Diéras; John Glaspy; Adam M Brufsky; Igor Bondarenko; Oleg N Lipatov; Edith A Perez; Denise A Yardley; Stephen Y T Chan; Xian Zhou; See-Chun Phan; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

5.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

6.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

7.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

8.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

9.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

10.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245
View more
  2 in total

1.  Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma.

Authors:  Johnny Duerinck; Paul M Clement; Frank Bouttens; Chantal Andre; Bart Neyns; Yves Staelens; Frank Van Fraeyenhove; Jean-Francois Baurain; Sylvie Luce; Lionel D'hondt; Eric Joosens; Pol Specenier; Vincent Verschaeve; Bertrand Filleul; Philippe Vroman; Barbara Stragier; Anne Rogiers
Journal:  J Neurol       Date:  2015-01-09       Impact factor: 4.849

2.  A method to assess target gene involvement in angiogenesis in vitro and in vivo using lentiviral vectors expressing shRNA.

Authors:  Wayne Blosser; Eliza Vakana; Lisa V Wyss; Michelle L Swearingen; Julie Stewart; Louis Stancato; Courtney M Tate
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.